CNSX:THC

Stock Analysis Report

Executive Summary

THC Biomed Intl Ltd. produces and sells medical marijuana in Canada.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has THC Biomed Intl's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-10.7%

THC

-10.0%

CA Pharmaceuticals

-0.3%

CA Market


1 Year Return

-84.8%

THC

-62.2%

CA Pharmaceuticals

0.9%

CA Market

Return vs Industry: THC underperformed the Canadian Pharmaceuticals industry which returned -62.2% over the past year.

Return vs Market: THC underperformed the Canadian Market which returned 0.9% over the past year.


Share holder returns

THCIndustryMarket
7 Day-10.7%-10.0%-0.3%
30 Day-26.5%-26.9%-2.1%
90 Day-37.5%-35.3%-1.5%
1 Year-84.8%-84.8%-62.2%-62.2%4.4%0.9%
3 Year-90.7%-90.7%84.7%83.3%15.7%5.4%
5 Yearn/a269.8%269.8%26.1%7.9%

Price Volatility Vs. Market

How volatile is THC Biomed Intl's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is THC Biomed Intl undervalued based on future cash flows and its price relative to the stock market?

1.16x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate THC's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate THC's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: THC is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: THC is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate THC's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: THC is good value based on its PB Ratio (1.2x) compared to the CA Pharmaceuticals industry average (1.9x).


Next Steps

Future Growth

How is THC Biomed Intl expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

92.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as THC Biomed Intl has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has THC Biomed Intl performed over the past 5 years?

-55.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: THC is unprofitable, and losses have increased over the past 5 years at a rate of -55.2% per year.

Accelerating Growth: Unable to compare THC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: THC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.6%).


Return on Equity

High ROE: THC has a negative Return on Equity (-74.68%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: THC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: THC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is THC Biomed Intl's financial position?


Financial Position Analysis

Short Term Liabilities: THC's short term assets (CA$6.9M) exceeds its short term liabilities (CA$2.5M)

Long Term Liabilities: THC's short term assets (6.9M) exceeds its long term liabilities (765.6K)


Debt to Equity History and Analysis

Debt Level: THC's debt to equity ratio (10%) is considered satisfactory

Reducing Debt: Insufficient data to determine if THC's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: THC has a high level of physical assets or inventory.

Debt Coverage by Assets: THC's debt is covered by short term assets (assets are 4.405770x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: THC has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: THC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -77.2% each year


Next Steps

Dividend

What is THC Biomed Intl's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%6.0%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate THC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate THC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if THC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if THC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of THC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

What is the CEO of THC Biomed Intl's salary, the management and board of directors tenure and is there insider trading?

4.8yrs

Average board tenure


CEO

John Miller 0

0yrs

Tenure

CA$62,400

Compensation

Mr. John Miller serves as Chief Executive Officer and President of THC Biomed Intl Ltd. and its Director since June 3, 2014. 


CEO Compensation Analysis

Compensation vs. Market: John's total compensation ($USD0.00) is too low to compare against companies of similar size in the Canadian market ($USD121.70K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Board Age and Tenure

4.8yrs

Average Tenure

Experienced Board: THC's board of directors are considered experienced (4.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyCA$7,45305 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares25,000
Max PriceCA$0.30
BuyCA$9,13504 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares31,500
Max PriceCA$0.29
BuyCA$48,05403 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares170,500
Max PriceCA$0.29
BuyCA$14,08701 Jun 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares50,000
Max PriceCA$0.28
BuyCA$22,00229 May 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares77,500
Max PriceCA$0.28
BuyCA$42,27028 May 19
John Miller
EntityIndividual
Role
Chief Executive Officer
Chief Executive Officer
Shares145,500
Max PriceCA$0.29
SellCA$84,60003 Apr 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares250,000
Max PriceCA$0.35
SellCA$21,48702 Apr 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares63,500
Max PriceCA$0.34
SellCA$45,61701 Apr 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares130,000
Max PriceCA$0.35
SellCA$71,58030 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares200,000
Max PriceCA$0.36
SellCA$63,60027 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares170,000
Max PriceCA$0.38
SellCA$19,25026 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares50,000
Max PriceCA$0.38
SellCA$54,20825 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares138,500
Max PriceCA$0.40
SellCA$24,20022 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares60,500
Max PriceCA$0.40
SellCA$154,00019 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares385,000
Max PriceCA$0.40
SellCA$171,93416 Mar 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares425,000
Max PriceCA$0.42
SellCA$10,00020 Jan 19
Jung Hee
EntityIndividual
Role
Member of the Board of Directors
Co-Founder
Shares20,000
Max PriceCA$0.50

Ownership Breakdown


Management Team

  • Dianne Szigety (65yo)

    Corporate Secretary

    • Tenure: 3.8yrs
  • Jung Hee

    Co-Founder

    • Tenure: 5.3yrs
    • Compensation: CA$62.40k
  • John Miller

    Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: CA$62.40k
  • Damien Reynolds

    Chief Capital Markets Officer

    • Tenure: 4.3yrs

Board Members

  • Jason Springett

    Member of Advisory Board

    • Tenure: 4.3yrs
  • Don Shaxon

    Member of Advisory Board

    • Tenure: 4.3yrs
  • Jung Hee

    Co-Founder

    • Tenure: 5.3yrs
    • Compensation: CA$62.40k
  • John Miller

    Chief Executive Officer

    • Tenure: 0yrs
    • Compensation: CA$62.40k

Company Information

THC Biomed Intl Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: THC Biomed Intl Ltd.
  • Ticker: THC
  • Exchange: CNSX
  • Founded: 2012
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$19.108m
  • Shares outstanding: 152.87m
  • Website: https://www.thcbiomed.com

Number of Employees


Location

  • THC Biomed Intl Ltd.
  • 1340 St. Paul Street
  • Kelowna
  • British Columbia
  • V1Y 2E1
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TFHDDB (Deutsche Boerse AG)YesCommon SharesDEEURSep 1988
THCCNSX (Canadian National Stock Exchange)YesCommon SharesCACADSep 1988
TFHDDB (Deutsche Boerse AG)COM NPVDEEURApr 2015

Biography

THC Biomed Intl Ltd. produces and sells medical marijuana in Canada. It also conducts research and development of the products and services related to cannabis for medical purposes. The company was founded ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:09
End of Day Share Price2019/10/11 00:00
Earnings2019/04/30
Annual Earnings2018/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)